COMMUNIQUÉS West-GlobeNewswire
-
Flyte Hops: Vision Jet Platform Seeks to Redefine Private Aviation
25/03/2026 -
Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update
25/03/2026 -
Declaration de NANOBIOTIX concernant une recente rumeur mediatique
25/03/2026 -
Jushi Holdings Inc. Announces First Settlement in Ongoing Hemp-Derived THC Litigation
25/03/2026 -
Enzon Announces Completion of the Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock
25/03/2026 -
Acentra Health Names New Senior Vice Presidents, Mohamed Karama and Nirav Dalal, to Drive Company Growth and Business Development
25/03/2026 -
SafeSpace Global to Attend ISC West 2026 to Strengthen Industry Relationships and Expand Strategic Pipeline
25/03/2026 -
SEMCAP Launches SEMCAP Beauty & Wellness to Capitalize on Opportunities in Burgeoning Longevity and Consumer Wellbeing Space
25/03/2026 -
Kestra Medical Technologies Named Finalist for 2026 GeekWire “Deal of the Year”
25/03/2026 -
ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026
25/03/2026 -
TOMI Environmental Solutions’ Binary Ionization Technology Approved in the Netherlands
25/03/2026 -
Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48
25/03/2026 -
ORYZON Strengthens Vafidemstat Patent Portfolio With U.S. Notice of Allowance
25/03/2026 -
SRx Health Solutions Hedges Decentralized Finance (DeFi) Portfolio with Investment in Gold and Reduces its Emerging Market Hedge
25/03/2026 -
AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program
25/03/2026 -
Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton Syndrome
25/03/2026 -
INVO Fertility Announces a 1:5 Reverse Stock Split Effective Pre-Market Opening on March 27, 2026
25/03/2026 -
Philips launches IntraSight Plus to simplify coronary interventions and advance precision care
25/03/2026 -
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease
25/03/2026
Pages